Literature DB >> 1924169

Simultaneous high-performance liquid chromatographic analysis of cefprozil diastereomers in a pharmacokinetic study.

W C Shyu1, U A Shukla, V R Shah, E A Papp, R H Barbhaiya.   

Abstract

Cefprozil, a new oral cephalosporin, consists of a 90:10 cis:trans isomer mixture. Sensitive, specific and reproducible high performance liquid chromatographic methods have been developed for the simultaneous quantification of the two stereoisomers of cefprozil in plasma and urine samples from human and rats. Cephalexin acted as the internal standard. Plasma protein was precipitated with acetonitrile and trichloracetic acid with subsequent extraction of acetonitrile. After vortexing and centrifuging, the aqueous phase was injected onto a reverse phase C8 column. Urine samples were acidified with sodium acetate buffer (pH 3.8) and then directly injected onto a reverse phase C18 column. The detector was set at 280 nm. These methods were applied to determine protein binding of both isomers in human and rat sera, and to perform a pharmacokinetic study in human. Results showed that both isomers bound moderately to serum proteins with no interference by the other isomer. The pharmacokinetic study in human indicated that cefprozil was well absorbed and the cis and trans isomers have similar pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1924169     DOI: 10.1023/a:1015896722170

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

1.  Phase I study of multiple-dose cefprozil and comparison with cefaclor.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Phase I study of single-dose BMY-28100, a new oral cephalosporin.

Authors:  R H Barbhaiya; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

4.  Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans.

Authors:  M N Dudley; W C Shyu; C H Nightingale; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

5.  Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

6.  In vitro activity of BMY-28100, a new oral cephalosporin.

Authors:  G M Eliopoulos; E Reiszner; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

7.  Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

8.  In vitro activity and serum protein-binding of cefaclor.

Authors:  F P Tally; N V Jacobus; M Barza
Journal:  J Antimicrob Chemother       Date:  1979-03       Impact factor: 5.790

9.  The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

Authors:  S Riegelman; P Collier
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

10.  BMY 28100, a new oral cephalosporin.

Authors:  F Leitner; T A Pursiano; R E Buck; Y H Tsai; D R Chisholm; M Misiek; J V Desiderio; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

View more
  7 in total

1.  Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.

Authors:  D P Nicolau; C O Onyeji; M Zhong; P R Tessier; M A Banevicius; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Effects of time of administration and posture on the pharmacokinetics of cefprozil.

Authors:  W C Shyu; C R Gleason; R H Barbhaiya
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

Review 3.  Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.

Authors:  L R Wiseman; P Benfield
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

4.  Effect of antacid on the bioavailability of cefprozil.

Authors:  W C Shyu; R B Wilber; K A Pittman; R H Barbhaiya
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

5.  Excretion of cefprozil into human breast milk.

Authors:  W C Shyu; V R Shah; D A Campbell; J Venitz; V Jaganathan; K A Pittman; R B Wilber; R H Barbhaiya
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

6.  Pharmacokinetic comparison with different assays for simultaneous determination of cis-, trans-cefprozil diastereomers in human plasma.

Authors:  Seung-Hyun Jeong; Ji-Hun Jang; Hea-Young Cho; Yong-Bok Lee
Journal:  J Pharm Anal       Date:  2020-07-05

7.  Spectrophotometric methods for the determination of cefprozil in bulk and dosage form.

Authors:  Elrasheed A Gadkariem; Mohammed M Mutasim; Kamal E E Ibrahim; Humeida A El-Obeid
Journal:  Int J Biomed Sci       Date:  2009-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.